77 results
6-K
EX-99.1
REPCF
Replicel Life Sciences Inc.
30 Nov 23
Condensed Consolidated Interim Financial Statements
1:05pm
to offset future profits.
4. Accounting Standards, Amendments, and Interpretations
New Standards, Amendments and Interpretations Effective … .
The $509,001 fee was allocated between contract costs, share issuance costs and as an offset to the fair value of the related warrants
6-K
EX-99.1
REPCF
Replicel Life Sciences Inc.
24 Oct 23
Condensed Consolidated Interim Financial Statements
11:10am
entity to satisfy certain tests when the losses are used to offset future profits.
4. Accounting Standards, Amendments, and Interpretations
New Standards … incurred in connection with the put obligation.
The $509,001 fee was allocated between contract costs, share issuance costs and as an offset
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
30 Aug 23
Notice of Annual General and Special Meeting of Shareholders
5:15pm
that are designed to hedge or offset a decrease in market value of equity securities granted as compensation or held, directly or indirectly, by the NEO
6-K
EX-99.1
REPCF
Replicel Life Sciences Inc.
9 Aug 23
Statement of Executive Compensation
7:41pm
contracts, equity swaps, collars, or units of exchange funds that are designed to hedge or offset a decrease in market value of equity securities granted
6-K
EX-99.1
REPCF
Replicel Life Sciences Inc.
30 May 23
Condensed Consolidated Interim Financial Statements
5:40pm
and as an offset to the fair value of the related warrants and as an offset to the fair value of the put liability. The finders/success fee was allocated … the interest - free component. The difference of $13,378 will be accreted to the loan liability over the term of the CEBA Loan and offset to other
6-K
EX-99.1
59rlykr495whv3 nfdco
29 Nov 22
Condensed Consolidated Interim Financial Statements
6:44pm
20-F/A
mfe4ios0jqca1w27qsl
12 Sep 22
Annual report (foreign) (amended)
6:17pm
6-K
EX-99.1
8hfe65yy
6 Sep 22
Condensed Consolidated Interim Financial Statements
12:42pm
6-K
EX-99.3
4oygk ssk3
7 Jul 22
RepliCel Provides Update on Private Placement
3:36pm
6-K
EX-99.4
0r5z9r woloy7na8k4f7
7 Jul 22
RepliCel Provides Update on Private Placement
3:36pm
6-K
EX-99.1
xofto76 8n0br0rksn8
7 Jul 22
Statement of Executive Compensation
1:43pm
6-K
EX-99.1
umgsc05kwi tv3b
30 Jun 22
Statement of Executive Compensation
11:16am
6-K
EX-99.1
kim379
30 Nov 21
Condensed Consolidated Interim Financial Statements
1:50pm
6-K
EX-99.1
u0dnl6e
18 Nov 21
Notice of Annual General and Special Meeting of Shareholders
10:36am
6-K
EX-99.1
6dhq ojtejjbj92olu
31 Aug 21
Condensed Consolidated Interim Financial Statements
1:45pm
6-K
EX-99.1
xuz 8wep41ba4f
1 Jun 21
Condensed Consolidated Interim Financial Statements
3:57pm
20-F/A
ex70xma969pgk5
31 Mar 21
Annual report (foreign) (amended)
12:00am